[시장보고서]순환 무세포 종양 DNA 시장 : 종양 유형별, 암 유형별, 기술별, 용도별, 지역별

순환 무세포 종양 DNA 시장 : 종양 유형별, 암 유형별, 기술별, 용도별, 지역별

Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region

상품코드 : 1741101

리서치사 : Coherent Market Insights

발행일 : 2025년 03월

페이지 정보 : 영문

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,531,000

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 7,000

￦ 10,159,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 10,000

￦ 14,514,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

순환 무세포 종양 DNA 시장은 2025년에는 92억 2,000만 달러로 추정되고, 2032년에는 390억 5,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 연평균 성장률(CAGR)은 22.9%를 나타낼 것으로 전망됩니다.

보고 범위		보고서 세부정보
기준 연도	2024년	시장 규모(2025년)	92억 2,000만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간 : 2025-2032년 CAGR :	22.90%	가치 예측(2032년)	390억 5,000만 달러

순환 종양 DNA(ctDNA)는 혈류를 순환하는 악성 세포와 종양의 DNA를 의미합니다. 죽은 세포는 DNA를 포함한 내용물을 혈류로 배출합니다. 순환 종양 DNA(ctDNA)에는 보통 암의 검출에 유용한 유전자 변화가 포함되어 있습니다. 암 검출검사가 치유율이 가장 높은 무증상 초기 단계에서 암을 발견할 수 있다면 그 임상적 유용성은 최대가 됩니다.

시장 역학

제품 포트폴리오를 확대하기 위해 시장 주요 기업이 제품 발매 등의 유기적 성장 전략을 채용하는 경우가 늘어나고 있으며, 예측 기간 중 시장 성장의 원동력이 될 것으로 전망됩니다. 예를 들어, 2022년 7월 차세대 분자 진단 회사인 빌리언투원은 최초의 종양학 액체 생검 제품인 노스스타 셀렉트와 노스스타 리스폰스를 출시한다고 발표했습니다. 이 제품은 현재 일부 학술 암 센터에서 연구용으로 사용할 수 있습니다. 이 패널은 빌리언투원의 독점적인 분자 계수 기술 또는 정량 계수 템플릿(QCT)을 활용하여 실행 가능한 변경 사항을 식별하는 데 주목할 만한 검출 한계를 달성합니다.

본 조사의 주요 특징

본 보고서는 세계의 순환 무세포 종양 DNA 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모 및 연간 평균 성장률(CAGR%)을 제공합니다.
또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 주요 인사이트도 제공합니다.
기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터를 바탕으로 세계의 순환 무세포 종양 DNA 시장 주요 기업 프로파일을 제공합니다.
본 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 향후 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관해서 정보에 근거한 의사 결정을 실시할 수 있습니다.
이 세계의 순환 무세포 종양 DNA 분석 보고서는 투자자, 공급업체, 제품 제조업체, 판매업자, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 하고 있습니다.
이해관계자는 세계의 순환 무세포 종양 DNA 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

Biocept, Inc.
Illumina, Inc.
Quest Diagnostics Incorporated
KURABO INDUSTRIES LTD
PerkinElmer chemagen Technologie GmbH
Biodesix
Guardant Health
QIAGEN
Sequenom, Inc.
Agilent Technologies, Inc.
Fluxion Biosciences Inc.
Natera, Inc.
Agena Bioscience, Inc.
Paragon Genomics, Inc.
Lucence Health Inc.
Eurofins Genomics
Thermo Fisher Scientific

제11장 섹션

조사 방법
출판사에 대해

KTH

영문 목차

영문목차

Circulating Cell-Free Tumor DNA Market is estimated to be valued at USD 9.22 Bn in 2025 and is expected to reach USD 39.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 9.22 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	22.90%	2032 Value Projection:	USD 39.05 Bn

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:
- Malignant Tumors
- Precancerous Tumors
Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Global Circulating Cell-Free Tumor DNA Market, By Technology:
- PCR
- Massively Parallel Sequencing
- Single Nucleotide Polymorphism
Global Circulating Cell-Free Tumor DNA Market, By Application:
- Cancer Diagnosis
- Targeting Therapeutics
- Prognosis Indication
Global Circulating Cell-Free Tumor DNA Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Biocept, Inc.
- Illumina, Inc.
- Quest Diagnostics Incorporated
- KURABO INDUSTRIES LTD
- PerkinElmer chemagen Technologie GmbH
- Biodesix
- Guardant Health
- QIAGEN
- Sequenom, Inc.
- Agilent Technologies, Inc.
- Fluxion Biosciences Inc.
- Natera, Inc.
- Agena Bioscience, Inc.
- Paragon Genomics, Inc.
- Lucence Health Inc.
- Eurofins Genomics
- Thermo Fisher Scientific

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Tumor Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Malignant Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Precancerous Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
PCR
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Massively Parallel Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Single Nucleotide Polymorphism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Application, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cancer Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Targeting Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Prognosis Indication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

9. Global Circulating Cell-free Tumor DNA Market, By Region, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Biocept, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Quest Diagnostics Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
KURABO INDUSTRIES LTD
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PerkinElmer chemagen Technologie GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biodesix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Guardant Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
QIAGEN
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sequenom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Fluxion Biosciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Natera, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agena Bioscience, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Paragon Genomics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lucence Health Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eurofins Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

11. Section

Research Methodology
About Us

한글목차

시장 역학

본 조사의 주요 특징

목차

제1장 조사의 목적과 전제조건

제2장 시장 전망

제3장 시장 역학, 규제, 동향 분석

제4장 세계의 순환 무세포 종양 DNA 시장 - COVID-19의 영향 분석

제5장 세계의 순환 무세포 종양 DNA 시장, 종양 유형별(2020-2032년)

제6장 세계의 순환 무세포 종양 DNA 시장, 암 유형별(2020-2032년)

제7장 세계의 순환 무세포 종양 DNA 시장, 기술별(2020-2032년)

제8장 세계의 순환 무세포 종양 DNA 시장, 용도별(2020-2032년)

제9장 세계의 순환 무세포 종양 DNA 시장, 지역별(2020-2032년)

제10장 경쟁 구도